5388 results about "Tumor cells" patented technology

Disclosed in the present invention are a quinazoline compound, and a pharmaceutical composition thereof and the use thereof. Provided in the present invention is a compound as represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compounds of the present invention have a good degradation effect on the KRAS protein with a G12D mutation, have a good inhibitory activity against the proliferation of tumor cells with a KRAS G12D mutation, and exhibit good pharmacokinetic properties.

In accordance with at least one aspect of this disclosure, there is provided an imaging agent, a including dye compound conjugated to an antigen specific targeting vector which can be particularly advantageous because their behavior in vivo can contribute to superior optical imaging properties, for example, by significantly increasing the target-to-background ratio of imaged tissues, leading to higher resolution imaging, and ultimately providing for better recognition of malignant tissue for resection and margin assessment and improved visualization during minimal invasive laparoscopic surgery, for example. A method of imaging tumor cells in a subject, can include, administering an imaging effective amount of an imaging agent according at least one embodiment of the invention; 2-4 hours after administration of the imaging agent, irradiating a region in the subject in which tumor cells are expected to be found with at a wavelength absorbed by the imaging agent; and detecting a signal from the imaging agent, thereby imaging the tumor cells, wherein the target-to-background ratio 2-4 hours after administration is from about 2.75 to about 15.

The invention discloses a colorectal cancer drug relocation method based on multi-omics integration. The system comprises a multi-omics data acquisition and preprocessing module, a tumor microenvironment analysis module, a specific disease network construction module, a multi-dimensional drug relocation module and a result evaluation module. And the tumor microenvironment analysis module comprises cell heterogeneity identification, cell map construction, cell annotation and tumor cell subset annotation. The specific disease network construction module comprises tumor feature expression program extraction, expression program screening, meta-program construction, clinical related meta-program recognition and specific disease protein interaction network construction. And the multi-dimensional drug relocation module comprises a module for identifying diseases by using a random walk algorithm, carrying out drug screening based on disturbance data, carrying out drug screening based on network proximity and carrying out comprehensive drug relocation. From the perspective of single cell data, element programs related to colorectal cancer survival are excavated, corresponding modules are designed, and the efficiency and precision of colorectal cancer targeted drug screening are improved.

The invention discloses a tumor cholesterol metabolism regulation microneedle patch and a preparation method, the microneedle patch comprises a needle tip and a backing which are connected, the needle tip comprises a needle tip body and nanoparticles loaded on the needle tip body, the nanoparticle is a manganese ion-doped organic metal framework, the outer layer of the manganese ion-doped organic metal framework is modified with a targeting agent, cholesterol oxidase and superoxide dismutase are carried on the manganese ion-doped organic metal framework, the targeting agent can target a CD44 receptor, and the organic metal framework can carry drugs. The targeted drug can enter tumor cells in a targeted mode, superoxide dismutase catalyzes superoxide anions overexpressed in the tumor cells to generate H2O2 and O2, O2 needed by catalysis is provided for cholesterol oxidase, cholesterol at the tumor site is consumed by the cholesterol oxidase, accumulation of 7-DHC is reduced, meanwhile H2O2 can be generated, and the cholesterol oxidase can be used for catalyzing the tumor site. H2O2 is catalyzed by manganese ions through a Fenton-like reaction to generate OH to induce tumor cells to generate ferroptosis, so that ferroptosis-immune synergistic treatment is realized.

The invention relates to application of a targeted inhibition circPDK1 reagent in preparation of an anti-esophageal cancer drug, and belongs to the field of biological medicines. The reagent for targeted inhibition of circPDK1 expression provided by the invention is shRNA or siRNA, and in-vivo and in-vitro experiments prove that the reagent can significantly inhibit circPDK1 expression and inhibit growth and migration of esophageal cancer tumor cells; after siRNA of targeted annular circPDK1 is packaged into efficient and low-toxicity LNP-siRNA, circPDK1 expression is specifically silenced, proliferation and migration of esophageal cancer tumors can be remarkably inhibited, and a basis is provided for clinical treatment and scientific research of esophageal cancer related circRNA.

The invention discloses an anti-PD-L1 antibody coupling drug and a preparation method thereof, belongs to the field of biological medicines, and is used for preparing anti-cancer drugs. The antibody coupling medicine is formed by coupling an anti-PD-L1 antibody and a payload through a linker, a light chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 1, a heavy chain variable region sequence of the antibody is a sequence recorded by SEQ ID NO: 2, the payload is an avixatecan derivative Dxd, and the ratio (DAR) of the payload to the antibody is 6-8. The antibody-conjugated drug has a better killing effect on PD-L1 positive tumor cells of human and dogs, and has fewer dimers and higher thermal stability at a high DAR value (DAR6-8), and an accelerated stability test shows that the antibody-conjugated drug has good structural stability and binding activity.

The invention relates to an anti-CD3 nano antibody, an anti-CD38 antibody and a bispecific antibody containing the anti-CD3 nano antibody and the anti-CD38 antibody. According to the invention, an anti-CD3 nano antibody and an anti-CD38 monoclonal antibody are excavated and prepared, humanized design is carried out to obtain antibodies with high affinity and specificity, and different configurations of bispecific T cell conjugation antibodies targeting CD3 and CD38 are further designed, so that the CD3 and CD38 dual-specificity T cell conjugation antibodies are obtained. The antigen binding activity, the T cell-mediated tumor cell killing effect and the T cell proliferation and activation function of the antibody are systematically evaluated in vitro, and experimental results show that the T cell conjugation antibody can effectively recruit and activate T cells and has a remarkable killing effect on CD38 positive tumor cells, and it is further verified that the antibody has remarkable in-vivo anti-tumor activity and has a good application prospect. Therefore, the polypeptide has high affinity, good pharmacological characteristics and development potential.

The invention discloses a tumor evolution trajectory prediction method and system based on image feature learning, and the method comprises the steps: obtaining the whole-process pathological section image data of a target type tumor patient, carrying out the analysis and screening of the image quality, constructing a pathological section screening strategy, and extracting a standard image; extracting tumor cell characteristics based on the standard image, performing grouping analysis on the cell characteristics of different time periods through a clustering algorithm, and determining tumor cell development characteristics; further constructing the cell development characteristics of multiple patients into a heterogeneity propagation network, simulating the tumor evolution process by using a random walk algorithm, and identifying the multi-branch evolution trajectory of the tumor; and finally, establishing a tumor evolution trajectory prediction model to predict the tumor development trend of the current patient. According to the method, the accuracy and interpretability of tumor evolution trajectory modeling can be improved, and reliable support is provided for clinical individualized diagnosis and treatment.

The invention relates to the field of multi-modal learning, in particular to a colorectal cancer drug chemotherapy reaction prediction system and a storage medium, and a computer program in the storage medium executes the following steps: constructing a PDO model and a PDOX model based on tumor cells; obtaining a standardized median inhibitory concentration value and a standardized relative tumor proliferation rate of the colorectal cancer patient by utilizing the PDO model and the PDOX model; based on the obtained medical record and pathological examination of the colorectal cancer patient, obtaining the age, ASA score, Ki-67 index, combined positive score and clinical outcome of the patient, and further constructing a sample set in combination with a standardized median inhibitory concentration value and a standardized relative tumor proliferation rate; and constructing a model for predicting the chemotherapy reaction of the colorectal cancer drug on the basis of multi-factor logistic regression, training and evaluating the model by using the sample set, and performing chemotherapy guidance on a to-be-treated colorectal cancer patient. The problems that in the prior art, chemotherapy reaction prediction of the colorectal cancer patient is not accurate enough and low in efficiency are solved.

The invention provides a breast cancer HER2 immunohistochemical digital slice automatic interpretation method, device and equipment and a storage medium. Relates to the technical field of digital pathological image analysis. Acquiring a full-slice image, automatically identifying an external contrast area and a tissue area through a multi-task head real-time instance segmentation model, and segmenting an ROI (Region of Interest) area of tumor cell aggregation; extracting image blocks by adopting a fixed sliding window based on the ROI region, and constructing a double-branch multi-task feature extraction model containing a backbone network: realizing HER2 expression pattern classification by an image block classification head, and outputting a continuous protein expression intensity quantized value by a dyeing intensity numerical head through regression analysis; and establishing a slice-level interpretation model, integrating the classification results and the intensity quantized values of all the image blocks, and outputting an automatic HER2 interpretation result. According to the invention, end-to-end analysis from cell-level characteristic quantification to slice-level diagnosis is realized, and an objective and quantifiable intelligent interpretation scheme is provided for HER2 immunohistochemical evaluation.

According to the GPX4 protein degradation agent and the application, the degradation agent serves as molecular glue to induce tumor cell ferroptosis and is different from an existing PROTAC technology, and the molecular glue can induce interaction between E3 ubiquitin ligase and target protein GPX4 and promote ubiquitination of the E3 ubiquitin ligase and the target protein GPX4. Compared with the existing GPX4 degradation agent, the molecular glue has the advantages of small molecular weight, high cell permeability and better druggability. The GPX4 molecular glue disclosed by the invention can be used for effectively degrading GPX4 and has a killing effect on various tumor cell lines. The preparation method is simple in synthesis route and mild in reaction condition, can be used for being developed into a new generation of GPX4 targeting drugs, and has great clinical application value and considerable market potential.

The invention discloses application of MUC12 gene in preparation of drugs for reducing rectal cancer liver metastasis, and belongs to the technical field of medical biology. According to the invention, the clear relation between colorectal cancer liver metastasis and fructose metabolism reprogramming is revealed from a molecular mechanism for the first time. The invention provides a brand-new therapeutic target and strategy by determining the brand-new transfer promoting factor MUC12 and the mediated fructose metabolism regulation effect thereof. Different from the traditional therapy only aiming at the strategies of tumor cell proliferation, blood supply and the like, the method disclosed by the invention intervenes aiming at a tumor nutrition metabolic pathway, and can weaken the metabolic adaptation and proliferation capacity of metastatic tumor cells in the liver more specifically. Experimental results show that the functions of targeted inhibition of MUC12 or downstream fructose metabolism key enzymes KHK and ALDOB thereof can significantly reduce the invasion and metastasis ability of tumor cells, and at the same time, normal growth of primary tumors cannot be significantly affected.

The invention discloses an OTX-015 (Ox-015) loaded cascaded responsive nano particle and a preparation method thereof. The nanoparticle has a three-layer core-shell structure, wherein the innermost layer is a cross-linked nanoparticle of chitosan and paclitaxel; the middle layer is a polydopamine layer loaded with a bromodomain inhibitor OTX-015; the outermost layer is a gelatin layer grafted with babali; wherein the cross-linked substance of the chitosan and the paclitaxel is a cross-linked substance containing a disulfide bond. The invention also provides a preparation method of the cascade responsive nano-particle and application of the cascade responsive nano-particle in preparation of an antitumor drug targeted delivery system. The nanoparticle provided by the invention improves the tumor microenvironment while activating in-vivo autoimmunity, and kills tumor cells by using photothermal therapy assisted chemotherapy drugs, so that the synergistic effect of chemotherapy / photothermal therapy / immunotherapy is realized, and a new idea is provided for clinical tumor treatment.

The invention relates to a curcumin-loaded MMP response type melittin nano-pellicle vesicle as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing curcumin entrapped lipidosome; then carrying out culture amplification on engineering bacteria carrying melittin recombinant plasmids, extracting cell membranes after removing cell walls, and carrying out ultrasonic treatment and membrane extrusion to obtain melittin cell membrane nano-vesicles; fusing the curcumin lipidosome and the cell membrane nano-vesicles in an ultrasonic extrusion mode to obtain fused vesicles; and finally, carrying out surface calcium phosphate mineralization treatment on the fused vesicles to obtain the curcumin-loaded MMP response type melittin nano pellicle vesicles. The nano mycofilm vesicle prepared by the invention can be used for preparing antitumor drugs, and the biocompatibility and in-vivo stability of nanoparticles are improved by introducing a calcium phosphate coating; through combined delivery of melittin and curcumin, the anti-tumor effect is enhanced, so that the growth and proliferation of tumor cells are inhibited.

The invention discloses a fluorescent colorimetric sensor for detecting circulating tumor cells and a preparation method of the fluorescent colorimetric sensor. The preparation method comprises the following steps: S4, adding a prepared detection antibody modified with horse radish peroxidase and used for detecting the circulating tumor cells, and incubating; s5, adding a Tris buffer solution and a H2O2 solution, and incubating; s6, preparing an EuMOF nanoflower solution; and S7, adding the EuMOF nanoflower solution and 3, 3 ', 5, 5'-tetramethyl benzidine to react, detecting the fluorescence intensity in the presence of circulating tumor cells with different concentrations by using a luminoscope, detecting the ultraviolet absorbance value in the presence of circulating tumor cells with different concentrations by using a multifunctional microplate reader, and constructing a fluorescence intensity-concentration working curve and an ultraviolet absorbance value-concentration working curve. The method is used for qualitative and quantitative analysis and detection of the circulating tumor cells, realizes bimodal signal response to the circulating tumor cells, and has high sensitivity and simplicity and convenience in operation.

The invention discloses organic nano composite hydrogel as well as a preparation method and application of the organic nano composite hydrogel, and belongs to the technical field of biological medicine delivery. The polysaccharide-based nano prodrug in the composite hydrogel can be subjected to surface protonation under the stimulation of a tumor extracellular slightly acidic environment, so that cellular uptake is promoted, low-pH / high-concentration glutathione in tumor cells is responded, intracellular aggregation and controllable release of the nano drug are realized, the retention time of the drug in the cells is prolonged, and the bioavailability of the drug is improved. The technical effect of killing tumor cells through combined chemotherapy is achieved. According to the preparation method disclosed by the invention, the release of the polysaccharide-based nano prodrug from the hydrogel and the tissue infiltration capacity are accelerated by adopting fluorinated orthoester, the infiltration of the polysaccharide-based nano prodrug to cells is increased, and then the drug-loaded compound is encapsulated by using gellan gum, so that the slow-release effect of the polysaccharide-based nano prodrug is enhanced; therefore, the efficient enrichment of the medicine at the tumor part is realized.

The invention provides a dual-targeting carrier material, a preparation method thereof and a preparation method of oleanolic acid nanoparticles wrapped by the dual-targeting carrier material, and belongs to the technical field of medicines. The oleanolic acid targeting nanoparticles are prepared by taking a dual-targeting high-molecular copolymer as a carrier material and adopting an emulsification-solvent evaporation method, so that the oleanolic acid can be protected from being quickly degraded, and the in-vivo circulation time of the oleanolic acid can be prolonged. Meanwhile, targeted delivery of oleanolic acid is realized through a targeted group, the concentration of the drug in tumor tissues is improved, and toxic and side effects on normal tissues are reduced. An MTT method is adopted, the inhibition effect of the oleanolic acid nanoparticles on cell growth is researched, and the result shows that the oleanolic acid targeting nanoparticles have a stronger effect of inhibiting tumor cell proliferation compared with an oleanolic acid raw material medicine.

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.

The invention discloses a multiple myeloma bone marrow image recognition system based on computer vision, relates to the technical field of cell recognition, solves the problem that traditional manual microscopic examination is large in limitation, and accurately recognizes burr change segments by conducting angle analysis on the edge contour of a feature area, so that the accuracy of recognition is improved. According to the comprehensive proportion of the burr change section on the overall edge contour, reliably judging whether the to-be-detected cell is a tumor cell or not, and calibrating and displaying the tumor cell in a gray image; according to the mode, the obvious difference of the tumor cells and normal cells in cell nucleus morphology is effectively utilized, rapid and accurate identification of the tumor cells is achieved, a visual and clear result is provided for clinical diagnosis, doctors are assisted to accurately judge multiple myeloma in time, the diagnosis efficiency and the treatment effect are improved, mean value processing and radial ratio analysis are conducted on contour area gray values, and the diagnosis accuracy is improved. The contour region associated with the cell nucleus can be accurately locked from the to-be-detected cell and is calibrated as the feature region, and a key cell nucleus feature basis is provided for tumor cell recognition.

The invention relates to the field of tumor cell therapy, in particular to application of T lymphocyte chimeric with a B7-H3 receptor to treatment of head and neck tumors, and provides an anti-B7-H3 scFv, the scFv comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises an HCDR region and an HFR region, and the light chain variable region comprises an LCDR region and an LFR region; compared with a wild type scFv sequence, the scFv sequence has the advantage that a plurality of amino acids with positive charges in the HFR region and / or the LFR region are mutated into amino acids without charges. According to the invention, positive charge plaques on the CAR surface of an scFv sequence of a B7-H3 human-derived monoclonal antibody MGA271 are changed in a charged amino acid mutation manner, so that a B7-H3. CAR-T cell is optimized, and it is proved that the B7-H3. CAR-T cell optimized by PCP can effectively kill B7-H3 positive tumor cells in vivo and in vitro; and a new method and thought are provided for clinical targeted treatment of B7-H3 positive solid tumors.

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention provides a nano-drug based on atomic layer deposition and a preparation method of the nano-drug, mesoporous silica is taken as a carrier, bimetallic nanoparticles are precisely deposited through ALD, and chemotherapeutic drugs and antibacterial components are loaded by combining amination and targeted PEG modification, so that the following functions are realized: (1) H2O2 in a tumor microenvironment is catalyzed to generate reactive oxygen species (ROS); removing fusobacterium nucleatum and damaging a biological membrane of the fusobacterium nucleatum; (2) GSH is consumed through Fenton reaction, and tumor drug resistance is reversed; and (3) the drug is released in pH response, and tumor cells are accurately killed. The invention further provides application of the nano-drug based on atomic layer deposition in treatment of related drug-resistant colorectal cancer induced by fusobacterium nucleatum, the process is controllable, the biocompatibility is excellent, the treatment effect on the drug-resistant colorectal cancer is remarkably improved, and the nano-drug has wide clinical application prospects.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention discloses a colorectal cancer radiotherapy sensitization medicine and application thereof, belongs to the field of biological medicine, and particularly relates to a colorectal cancer radiotherapy sensitization medicine which comprises active pharmaceutical ingredients and a solvent, the active pharmaceutical ingredients comprise doxorubicin and a nitrogen-containing compound, the nitrogen-containing compound comprises quinoline-6-carbohydrazide and N-benzyloxymethyl-4-nitroimidazole, and the nitrogen-containing compound comprises quinoline-6-carbohydrazide and The colorectal cancer radiotherapy sensitization medicine disclosed by the invention focuses on a key driving gene FOXP4 for colorectal cancer radiotherapy resistance, and FOXP4 protein is degraded through a ubiquitin-proteasome way, so that not only can the sensitivity of tumor cells to radiotherapy be remarkably improved and tumor growth be inhibited, but also damage to normal tissues is reduced; moreover, the problem of drug resistance easily generated by a traditional method is effectively avoided, the research and development cost is greatly reduced, clinical transformation is accelerated, and the method has a good clinical application prospect.

The invention discloses an HER2 expression state evaluation method and device, equipment and a storage medium. The method comprises the following steps: dividing an HE dyeing image of a target object into a plurality of first sub-images, and determining an infiltration area of the HE dyeing image through the first sub-images; dividing the IHC dyeing image of the target object into a plurality of second sub-images, and determining tumor cells of various dyeing degrees in the IHC dyeing image through the second sub-images; determining a first expression state of the target object HER2 according to the infiltration area and the tumor cells; under the condition that the first expression state is IHC < 2 + >, determining a primary focus area in the image of the target object, and obtaining image features through the primary focus area; obtaining HE features and IHC features through the infiltration area and the tumor cells, and generating multi-modal features according to the image features, the HE features and the IHC features; and inputting the multi-modal features into the first classification network to obtain a second expression state of the target object HER2.

The invention discloses a polypeptide pka15 with a function of inhibiting tumor cell proliferation and application of the polypeptide pka15. The amino acid sequence of the polypeptide pka15 with the function of inhibiting tumor cell proliferation is shown as SEQ ID NO: 1, the nucleotide sequence of the polypeptide pka15 is shown as SEQ ID NO: 2, and the polypeptide pka15 shows good tumor cell proliferation resistance and can be used for preparing drugs or reagents for inhibiting tumor cell proliferation. The polypeptide pka15 disclosed by the invention is simple to synthesize, easy to prepare on a large scale, low in immunogenicity, low in cost, remarkable in effect and convenient for subsequent clinical application and popularization, thereby having a wide application prospect.

The invention relates to the field of image analysis, in particular to a colon cancer lymph node metastasis risk prediction method and system based on image analysis. The method comprises the following steps: acquiring a pathological section scanning image, carrying out layer-by-layer downsampling and feature reconstruction, and generating pathological section topological features; carrying out adaptive clustering analysis and multi-parameter fusion evaluation on the basis of the pathological section topological features to obtain independent migration evaluation values of individual tumor cells; performing tumor metastasis branch analysis according to the independent migration evaluation value, and constructing a metastasis branch path distribution diagram; extracting an immunohistochemical staining image of a patient to obtain immune cell space distribution data; and performing multi-region lymphatic metastasis simulation and metastasis risk situation prediction based on the immune cell spatial distribution data and the metastasis branch path distribution diagram to obtain a final metastasis risk assessment result. According to the method, the lymph node metastasis risk is accurately and efficiently analyzed, and the credibility of a pathological analysis result is improved.

The invention provides an anti-cancer active component optimization method for breast cancer treatment, which comprises the following steps: analyzing a potential interference path of an anti-cancer active component on immune system cell viability by adopting a computational chemistry simulation method according to a preliminary structural function mapping relationship, and determining a specific molecular mechanism range of immune system weakening; according to the synergistic effect evaluation result, optimizing the structural parameters of the active components through a molecular docking algorithm, adjusting the binding affinity of the active components with tumor cell targets and pathogenic bacteria targets, and determining a final structural optimization scheme; aiming at the final structure optimization scheme, verifying the expression of the modified active component on tumor inhibition and antibacterial ability by adopting simulation data of an in-vitro activity test, and obtaining a verification data set of comprehensive performance; and aiming at the updated active component design data, through a multi-objective optimization model, balancing the synergism of an anti-cancer effect and a health protection mechanism, and determining a final compound structure configuration suitable for complex requirements of a clinical environment.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.